Skip to main content

Overview

Ions and Cellular Homeostasis

There are three areas of research in the lab all of which focus on receptor mediated regulation of plasma membrane transporters. They are briefly described below. I. Ionic Homeostasis in Hypovolemia: Renal Mechanisms The overall objective of this project is to elucidate the renal mechanisms in the intercalated cells of the cortical collecting duct involved in the adaptation to hypovolemia as may occur in such conditions as diarrhea, diuretic use, and congestive heart failure. K -sparing is an important homeostatic component in response to hypovolemia but the means by which K is conserved when NaCl is reabsorbed in the cortical collecting duct is not understood. We are testing the hypothesis that the intercalated cells of the cortical collecting duct are responsible for K reabsorption and is effected by two H -K -ATPase enzymes localized to the luminal side of the intercalated cells. The mechanism by which Cl- reabsorption accompanies Na reabsorption from lumen to blood is also being examined by investigating the role of an apical Cl-/HCO-3 exchanger found in the base secreting intercalated cell sub-type. It is predicted that the net effect of these processes is to ensure that K sparing, and acid-base homeostasis accompanies NaCl reabsorption. Furthermore, it is believed that angiotensin is the hormone responsible for mediating the chronic effects of volume depletion on H -K -ATPase activity and apical Cl-/HCO3- exchanger activity via AT1A receptor activation. The overall premise for conducting these experiments is that if we understand the physiological basis by which the body normally conserves K then we will also have identified a target that potentially can be exploited for therapy of disorders of K metabolism. II. Histamine H3-Receptors in Cardiac Sympathetic Nerve Endings: Role in Norepinephrine Release

Highlights

  1. 1
    Frontiers in medicine · 2023
    PMID: 36910476PMCID: PMC9995661DOISenior author15 citations

Publications

59 publications

Active

1 grant
  • Sub-PI
    Fast Track Phase II - Platform technology to identify and develop first-in-class anti-fibrotic therapeutics through inhibition of collagen CP4H
    National Heart, Lung, and Blood Institute · 2024–2027 · via Adiutrix Therapeutics, LLC· 2 renewals
    R42HL176297-02
Completed grants (4)
  • Sub-PI
    Development of Small Molecule Inhibitors of Collagen Prolyl-4 Hydroxylase (CP4H) to Treat Fibrosis
    NYSTAR · 2024–2025 · via Cornell University - Ithaca
    CUI 235199-01
  • PI
    Development of Novel Drugs to Treat Fibrosis Through Modulation of Collagen Prolyl-4-Hydroxylase
    Daedalus Fund for Innovation (Weill Cornell) · 2020–2023BioPharma Alliance
    DFI 202950-02
  • KP
    Histamine Receptor/Norepinephrine in Cardiac Dysfunction
    National Heart, Lung, and Blood Institute · 2010–2015
    R01HL034215-37EWO
  • PI
    Mast-Cell Renin and Local ANG II Formation
    National Institute of Diabetes and Digestive and Kidney Diseases · 2007–2011
    R01DK060726-08 EW

News mentions